American Gene Technologies, announced that Gaingels invested in the company. This investment is to support the Phase 1 clinical trial of an HIV cure. The Phase 1 human trial is investigating the safety of AGT103-T, a single dose, autologous cell therapy intended to cure the disease.This investment places Gaingels, which is the leading investment syndicate in support of and representing the LGBTQ community and allies in the venture capital space and many other private investors who believe deeply in American Gene Technologies mission, rapid drug development platform, and gene and cell therapy programs for HIV, cancer, and PKU.
Gaingels is an investment network of 1000+ investors focused on high-growth venture-backed companies who embrace LGBT+ leadership. It works to support its portfolio companies in identifying and recruiting diverse leadership talent, fostering a vibrant global community of industry leaders, investors, operators, and entrepreneurs who share a common goal for positive social change through business and successful investments.
Lorenzo Thione, Managing Director of Gaingels said that as the largest investor network it is focused on supporting and investing in the best venture-backed companies that embrace and value diverse leadership, including LGBTQ+. Gaingels is also proud to participate in this mission. Its mission hits uniquely close to home for the LGBTQ+ community given the Gene company to focus on creating functional immunity and thus an effective cure for HIV.